GeronGERN
GERN
About: Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Employees: 229
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
96% more call options, than puts
Call options by funds: $1.77M | Put options by funds: $901K
48% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 66
0.91% less ownership
Funds ownership: 80.95% [Q4 2024] → 80.03% (-0.91%) [Q1 2025]
5% less funds holding
Funds holding: 284 [Q4 2024] → 269 (-15) [Q1 2025]
22% less first-time investments, than exits
New positions opened: 46 | Existing positions closed: 59
50% less funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 3 (-3) [Q1 2025]
53% less capital invested
Capital invested by funds: $1.73B [Q4 2024] → $812M (-$921M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1.50
1%
downside
Avg. target
$1.50
1%
downside
High target
$1.50
1%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Scotiabank Greg Harrison | 1%downside $1.50 | Sector Perform Downgraded | 8 May 2025 |
Financial journalist opinion
Based on 4 articles about GERN published over the past 30 days
Positive
Seeking Alpha
1 week ago
Conservative Vision Of A Positive Future For Geron
This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter sales of the imetelstat did not meet stock market expectations; consequently, share price went down by 70%. Conservative analysis of the disease, epidemiology, drug properties, and competition suggests a substantial market opportunity.
Neutral
Business Wire
2 weeks ago
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GERN--Geron announces presentations on RYTELO® (imetelstat) at 2025 ASCO Annual Meeting and EHA 2025 Congress.
Neutral
Business Wire
3 weeks ago
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 137,000 shares of common stock, to six newly hired employees as an inducement material to their acceptance of employme.
Neutral
GlobeNewsWire
1 month ago
GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company.
Neutral
Accesswire
1 month ago
Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148178&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 month ago
Geron Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. May 12 2025 Deadline to file Lead Plaintiff Motion.
LOS ANGELES, May 12, 2025 (GLOBE NEWSWIRE) -- Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
Accesswire
1 month ago
Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148118&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers - GERN
NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-02563, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Geron securities between February 28, 2024 and February 25, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Neutral
GlobeNewsWire
1 month ago
The Gross Law Firm Notifies Shareholders of Geron Corporation(GERN) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Geron Corporation (NASDAQ: GERN).
Neutral
Accesswire
1 month ago
Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025 - GERN
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=148086&wire=1 or contact Joseph E. Levi, Esq.
Charts implemented using Lightweight Charts™